15,125 Shares in DexCom, Inc. $DXCM Bought by Western Financial Corp CA

Western Financial Corp CA acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,125 shares of the medical device company’s stock, valued at approximately $1,305,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Reflection Asset Management purchased a new stake in DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom in the first quarter worth $25,000. Elevation Wealth Partners LLC raised its stake in shares of DexCom by 61.0% in the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after purchasing an additional 152 shares during the last quarter. GK Wealth Management LLC purchased a new position in shares of DexCom in the third quarter worth $35,000. Finally, Wellington Grp LLC lifted its holdings in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on DXCM shares. UBS Group set a $96.00 price objective on DexCom and gave the stock a “buy” rating in a report on Tuesday, July 28th. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research note on Monday, August 3rd. Mizuho set a $100.00 target price on shares of DexCom in a research report on Tuesday. Piper Sandler restated an “overweight” rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Finally, Robert W. Baird set a $105.00 price objective on shares of DexCom in a research report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $92.43.

Insider Transactions at DexCom

In other DexCom news, EVP Jereme Sylvain sold 3,638 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the sale, the executive vice president owned 146,828 shares in the company, valued at $12,226,367.56. The trade was a 2.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Sayer sold 26,756 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the transaction, the insider owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 49,313 shares of company stock valued at $3,945,875. 0.28% of the stock is owned by corporate insiders.

DexCom Price Performance

DXCM traded down $1.59 on Wednesday, hitting $83.47. 3,479,711 shares of the company’s stock traded hands, compared to its average volume of 4,992,459. The company’s 50 day simple moving average is $87.49 and its 200-day simple moving average is $75.61. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The firm has a market cap of $31.50 billion, a price-to-earnings ratio of 32.99, a P/E/G ratio of 1.44 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the company posted $0.48 EPS. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

About DexCom

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.